ABSTRACT

While the potential therapeutic utility of angiotensin-converting enzyme 2 (ACE2) is well established, the clinical development of ACE2 drugs has been limited, likely due in part to the short half-life of the protein. In contrast, Ig-like ACE2 fusion proteins have exhibited greatly extended plasma half-life in vivo, and they have been shown to have a potent neutralization effect against SARS-CoV-2. Clinical investigation of Ig-like ACE2 fusion proteins as COVID-19 interventions is thus warranted.

中文翻译：

---

Ig样ACE2蛋白疗法：在COVID-19大流行期间发展的复苏。

摘要

尽管已经建立了血管紧张素转换酶2（ACE2）的潜在治疗效用，但ACE2药物的临床开发受到了限制，这可能部分是由于该蛋白的半衰期短所致。相反，Ig样ACE2融合蛋白在体内的血浆半衰期大大延长，并且已显示出对SARS-CoV-2的有效中和作用。因此，有必要对Ig样ACE2融合蛋白作为COVID-19干预进行临床研究。